Trospium Chloride XR in Obese Female Patients With Overactive Bladder

Study Identifier
MA-SXR-09-003
CT.gov Identifier
NCT00932022
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Obesity or Weight Loss
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • Trospium Chloride, Extended Release (XR)
    • Phase
    Phase 4
    Sex
    Female
    Age
    18 - 75 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence * Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit). * Obese
    Exclusion Criteria:
    * Chronic kidney failure * Abdominal bypass surgery for obesity * Moderate or severe memory impairment * Uncontrolled narrow angle glaucoma * Uncontrolled systemic disease * Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia

    Protocol Summary

    This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

    Study Locations

    Location
    Status
    Location
    La Mesa, California, United States
    Status
    Not applicable